GlassScriptPhysician profile
Ryan Andrew Stevens
NPI 1417279068
$13,642.21
in general payments reported to CMS, 2019-2025
38 companies · $2,000 in 2025
The $2,000 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,548 · 2020: $1,229 · 2021: $2,183 · 2022: $2,372 · 2023: $2,364 · 2024: $1,947 · 2025: $2,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,211 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,210.98 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,880.12 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,445.91 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $1,232.04 | 2019-2025 | Otezla, Enbrel |
| Lilly USA, LLC | $1,002.32 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $850.90 | 2020-2025 | Ilumya, Winlevi, Absorica Ld |
| Pfizer INC. | $717.42 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $624.75 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $604.38 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $577.20 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $558.14 | 2019-2025 | Jublia |
| Genzyme Corporation | $528.56 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $387.46 | 2022-2025 | Sotyktu |
| Incyte Corporation | $376.38 | 2021-2025 | Opzelura |
| Celgene Corporation | $237.67 | 2019 | |
| Galderma Laboratories, L.P. | $155.16 | 2022-2025 | Nemluvio, Aklief |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $140.03 | 2025 | Vtama |
| Dermavant Sciences, INC. | $133.54 | 2023-2024 | Vtama |
| Leo Pharma INC. | $124.67 | 2019-2025 | Adbry |
| Stemline Therapeutics INC. | $124.30 | 2019 | |
| Janssen Scientific Affairs, LLC | $109.32 | 2019 | |
| Argenx US, INC. | $108.02 | 2023 | Vyvgart |
| Almirall LLC | $95.57 | 2019-2025 | Seysara |
| Arcutis Biotherapeutics, INC. | $88.55 | 2023 | |
| Vyne Pharmaceuticals INC. | $74.89 | 2020-2021 | |
| Dermira, INC. | $73.85 | 2019-2021 | |
| Prugen, INC. Pharmaceuticals | $71.76 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $52.67 | 2023-2025 | |
| Springworks Therapeutics, INC. | $49.85 | 2025 | Gomekli |
| Lnhc, INC | $41.42 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.21 | 2024 | Spevigo |
| Krystal Biotech INC | $27.57 | 2023 | Vyjuvek |
| Oxford Immunotec USA INC | $23.75 | 2021 | |
| Biofrontera INC. | $21.58 | 2021-2022 | |
| Epi Health, LLC | $17.94 | 2019 | |
| Botanix Sb INC | $14.87 | 2025 | Sofdra |
| Boston Scientific Corporation | $14.42 | 2024 | |
| Mission Pharmacal Company | $14.32 | 2021 | |
| Journey Medical Corporation | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.